HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.

Abstract
Murine alveolar macrophages (AM) can be rendered tumoricidal after the i.v. injection of multilamellar vesicles (MLV) containing muramyl dipeptide (MDP) at a minimum dose of approximately 0.6 micrograms or less than a 10-fold dilution of cellfree culture supernatants from mitogen-stimulated F-344 rat lymphocytes rich in macrophage-activating factor (MAF) activity. Neither MAF at dilutions exceeding 1/10 nor MDP at doses lower than approximately 0.6 micrograms activated AM in situ to become tumor cytotoxic. The combination of these agents at subthreshold amounts (MAF 1/20, MDP 0.3 microgram), however, activated AM to significant levels of cytotoxicity. The synergism between MAF and MDP encapsulated in liposomes was also observed in therapeutic studies of mice bearing well established, spontaneous lung and lymph node metastases. Multiple i.v. injections of liposomes containing either 6.25 micrograms MDP or a 1/2 dilution of MAF resulted in the long-term survival (greater than 250 days) of 30% of the treated mice. Neither liposomes containing MAF at a 1/20 dilution nor MDP at doses lower than 0.6 microgram were therapeutically effective. Multiple injections of liposomes containing subthreshold amounts (MAF 1/20; and MDP 0.3 micrograms) of these agents, however, resulted in 50% survival in the treated group. These data allow us to conclude that the encapsulation of MAF and MDP within the same MLV is more efficient in inducing the destruction of metastases than either agent administered alone.
AuthorsI J Fidler, A J Schroit
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 133 Issue 1 Pg. 515-8 (Jul 1984) ISSN: 0022-1767 [Print] United States
PMID6373933 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Liposomes
  • Lymphokines
  • Macrophage-Activating Factors
  • Acetylmuramyl-Alanyl-Isoglutamine
Topics
  • Acetylmuramyl-Alanyl-Isoglutamine (therapeutic use)
  • Animals
  • Cytotoxicity, Immunologic
  • Drug Synergism
  • Immunotherapy
  • Liposomes (administration & dosage)
  • Lung Neoplasms (secondary, therapy)
  • Lymphatic Metastasis
  • Lymphokines (therapeutic use)
  • Macrophage Activation
  • Macrophage-Activating Factors
  • Macrophages (immunology)
  • Male
  • Melanoma (immunology, therapy)
  • Mice
  • Mice, Inbred C57BL

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: